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Abstract
Adenoviruses are common pathogens, mostly targeting ocular, gastrointestinal and respira-
tory cells, but in some cases infection disseminates, presenting in severe clinical outcomes.
Upon dissemination and contact with blood, coagulation factor X (FX) interacts directly with
the adenovirus type 5 (Ad5) hexon. FX can act as a bridge to bind heparan sulphate proteo-
glycans, leading to substantial Ad5 hepatocyte uptake. FX “coating” also protects the virus
from host IgM and complement-mediated neutralisation. However, the contribution of FX in
determining Ad liver transduction whilst simultaneously shielding the virus from immune at-
tack remains unclear. In this study, we demonstrate that the FX protection mechanism is
not conserved amongst Ad types, and identify the hexon hypervariable regions (HVR) of
Ad5 as the capsid proteins targeted by this host defense pathway. Using genetic and phar-
macological approaches, we manipulate Ad5 HVR interactions to interrogate the interplay
between viral cell transduction and immune neutralisation. We show that FX and inhibitory
serum components can co-compete and virus neutralisation is influenced by both the loca-
tion and extent of modifications to the Ad5 HVRs. We engineered Ad5-derived HVRs into
the rare, native non FX-binding Ad26 to create Ad26.HVR5C. This enabled the virus to inter-
act with FX at high affinity, as quantified by surface plasmon resonance, FX-mediated cell
binding and transduction assays. Concomitantly, Ad26.HVR5C was also sensitised to im-
mune attack in the absence of FX, a direct consequence of the engineered HVRs from Ad5.
In both immune competent and deficient animals, Ad26.HVR5C hepatic gene transfer was
mediated by FX following intravenous delivery. This study gives mechanistic insight into the
pivotal role of the Ad5 HVRs in conferring sensitivity to virus neutralisation by IgM and clas-
sical complement-mediated attack. Furthermore, through this gain-of-function approach we
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demonstrate the dual functionality of FX in protecting Ad26.HVR5C against innate immune
factors whilst determining liver targeting.
Author Summary
Adenoviruses are mostly considered self-limiting pathogens associated with respiratory,
gastrointestinal and ocular infections; however, in immunocompromised subjects dissemi-
nated Ad infection can occur with life-threatening consequences. Many human Ads are
capable of binding to coagulation factor X (FX). Following intravenous administration in
animal models, FX binds directly to the major Ad capsid protein, the hexon, which subse-
quently results in virus accumulation in the liver. FX coating Ad5 also acts to shield against
immune neutralisation via natural IgM antibodies and the classical complement system.
Here we show that FX protection is not a conserved mechanism amongst Ads and identify
the Ad5 hexon hypervariable regions (HVR) as the capsid proteins targeted by this host
defense pathway. Furthermore, we show that genetic inclusion of Ad5 HVRs onto a native
non-FX binder Ad26 to be sufficient to confer sensitivity to immune attack in vitro and in
vivo. Using intravenous administration, we determine the significance of FX binding to
the Ad5-derived HVRs with respect to defending the virus from neutralisation whilst me-
diating virus tropism. Our study gives new insight into the role of the viral HVRs and of
FX at the interface between virus and host defense mechanisms.
Introduction
For the immunocompromised host, human adenoviruses (Ad) have emerged as a significant
pathogen capable of exploiting the impaired immunological response and becoming invasive,
manifesting in prolonged, severe and life threatening conditions [1–5]. There are seven human
species (A-G) of this common non-enveloped, double-stranded DNA virus. Whilst in healthy
individuals infections are self-limiting, targeting defined tissues such as the lung, eye and gastro-
intestinal system over a short time frame, disseminated Ad infections occur when immunity is
low (e.g. sufferers of hereditary immune deficiencies, patients undergoing immunosuppressive
treatment [1–5]). Systemic infections can culminate in serious and diverse clinical syndromes,
ranging from fulminant hepatic failure, coagulopathy, hemorrhagic cystitis, myocarditis, en-
cephalopathy, nephritis to multi-organ failure [2,6]. The immunocompromised patient popula-
tion is expanding due to increased use of immunosuppressive therapies (e.g. cytotoxic drugs)
and consequently Ads are gaining increased recognition as a clinical problem. The presence of a
high viral load in the blood is often strongly indicative of a severe outcome [5,6]. Incidence of
infection is approximately 2.5–47% in stem cell transplant recipients, whilst paediatric trans-
plantation patients are more prone to the disseminated disease, with mortality rates reaching up
to 70% [5,7,8]. Despite the high risk, there is no FDA approved drug specific to treating Ad in-
fection and therapeutic options can be limited. Advancing our knowledge of the complex mech-
anisms underlying Ad5 infection in vivo is of great importance.
Using species C Ad2/5 as the prototype, the in vitro infection pathway has been very well doc-
umented. Studies have finely detailed the individual steps from virus binding via the fiber knob
protein to the primary cell surface coxsackie and adenovirus receptor (CAR) [9], engagement of
the Ad penton base with αvβ3/5 integrins leading to internalization [10] and subsequent traffick-
ing from endosomes to nuclear import [11,12]. However, the lack of suitable animal models,
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which allow viral replication and closely mimic the human immune system, has challenged the
study of Ad infection in vivo. Nevertheless an abundance of valuable information has been gained
about viral spread, immune responses and methods to combat such, especially from its populari-
ty as a viral vector for gene therapy, vaccination and virotherapy protocols. Of the 60+ human
Ads identified [13], Ad5 is the virus-based gene transfer vector most frequently employed. Con-
comitantly, Ad5 is also one of the most seroprevalent of the family. The use of Ad5 as a viral vec-
tor has deepened our understanding of virus:host binding events, involvement of innate and
adaptive immunity and of the factors leading to the substantial accumulation of Ad5 particles in
the liver following bolus injection into the bloodstream.When administered intravenously (I.V.)
the virus rapidly encounters a multitude of interactions with circulating blood components.
These include virion neutralisation by pre-existing antibodies [14], sequestration by Kupffer cells
[15], MARCO+-expressing splenic macrophages [16], polymorphonuclear leukocytes [17], natu-
ral IgM and complement opsonisation [18,19]. Binding to platelets [20,21], erythrocytes [22,23],
and blood coagulation factors [24–26] all contribute to the substantial interplay between the
virus and host. Dissecting the precise interactions which occur in vivo is key to our understanding
of the virus infection pathways partnered with an individual’s defence mechanisms.
Previous work suggests that Ads belonging to species C (Ad1, Ad2 and Ad5) are more com-
monly associated with disseminated disease than other types and have been implicated in severe
hepatic failure [5,8]. Hepatitis is a frequent and serious consequence of systemic Ad infections
[27–29]. Coagulation factor X (FX) plays a fundamental role in determining the characteristic he-
patic tropism of Ad5 [24–26]. Selectively blocking FX prevents Ad liver transduction in rodent
and non-human primates following I.V delivery of virus [30–32]. FX binds with nanomolar
affinity to the Ad5 hexon hypervariable regions (HVR), and acts as a bridge to attach the virus
to N andO-linked heparan sulphate proteoglycans (HSPG) on the surface of hepatocytes
[24,33,34]. Crystallographic and cryogenic electron microscopy identified contact points within
and around Ad5 HVR5 and HVR7 which are responsible for interacting with the FX Gla (γ-car-
boxylated glutamic acid) domain [32]. Genetically swapping regions or specific amino acids with-
in the Ad5 HVR5 and HVR7 for those of a non-FX-binding Ad (e.g. species D Ad48 or Ad26)
has proven an effective strategy to abrogate the FX interaction and diminish liver transduction
[32,35]. In addition to binding the FX Gla domain at the HVR7 amino acid motif T423-E424-
T425, Ad5 is also capable of interacting with coagulation factor VII (FVII) at these points [36].
However, FVII does not support Ad5 transduction as it binds to the virus in an alternate orienta-
tion to FX, with dimerization of the FVII serine protease domains disguising potential HSPG re-
ceptor binding sites [36]. Further to its influence on liver transduction, Doronin et al. showed
that FX coating the virus triggers recognition by the innate immune system via nuclear factor-κB
(NFκB) activation and subsequent TLR4/TRAF6/NFκB-mediated inflammation, an effect absent
when Ad5 was genetically manipulated to be devoid of FX binding [37].
Recent work by Xu et al. has produced additional insight into the function of FX in adenovi-
rus biology [19]. They indicated a role for FX in protecting Ad5 from attack by natural IgM
antibodies and the classical complement system upon exposure to murine blood [19]. In co-op-
eration with IgM, complement activation acts as an innate host defense mechanism and has
previously been shown to result in neutralisation of invading pathogens including Ads
[18,19,38]. In vitro data demonstrated that FX can prevent Ad5 from this neutralisation when
incubated with murine serum [19]. In contrast to studies in wild-type mice, the Ad5:FX inter-
action was not essential for liver transduction in mice deficient in natural antibodies or the
complement components C1q and C4 [19]. Instead FX binding to Ad5 acted as a protective
"shield", decorating the viral capsid and preventing natural IgM and classical complement me-
diated inhibition of Ad gene transfer [19]. This study has led to some speculation surrounding
the impact of FX in determining Ad liver tropism.
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It is evident that blood components influence Ad tropism, whilst other interactions (e.g. Kupf-
fer cell uptake) remain dominant barriers to widespread Ad dissemination. Here, we studied the
binding events and mechanisms deciding the fate of the virus in circulation. We attempted to dis-
sect the importance of these interactions in determining viral cellular uptake and tropism. In this
study we used genetically mutated Ad vectors to identify key hexon regions responsible for IgM
and complement-mediated attack. The Ad5 HVRs were identified as the critical viral capsid com-
ponents. We then incorporated these regions and FX binding capability onto a non-FX-binding
Ad26 background. We utilised this novel vector to investigate the significance of FX and the role
of the Ad5 HVRs in the interplay between viral immune recognition and tropism in vivo.
Results
Ad5 hexon hypervariable regions are required for IgM and classical
complement-mediated neutralisation
FX coating Ad5 shields the virus against IgM and classical complement-mediated immune at-
tack [19]. Many other Ad types also bind to human FX (hFX) [24]. However it is unknown
whether they are sensitive to neutralisation via the same pathway. Therefore, we compared the
sensitivity of a selected panel of Ad vectors based on different species/types; the FX-binding
Ad5, Ad35 and Ad50, and non-binding Ad48 and Ad26 [24] to neutralisation by murine
serum in vitro. When Ad5 was incubated with C57BL/6 serum there was a significant increase
in transduction compared to the media control, likely due to the presence of native FX in the
murine serum (Fig. 1A). However when serum was pretreated with X-bp (binds the FX Gla do-
main blocking Ad:FX interaction [24]) Ad5 gene transfer was dramatically reduced, to levels
significantly below control conditions, consistent with previous results [19] (Fig. 1A). This
demonstrates that in the absence of FX Ad5 is sensitive to neutralisation by murine serum
components [19]. In contrast, Ad35, Ad50, Ad48 and Ad26-mediated cell transduction was
not affected by serum regardless of the presence of X-bp (Fig. 1A), indicating that these vectors
are not sensitive to the same mechanism that mediates Ad5 neutralisation. It is noteworthy
that the overall charge in the region of the Ad5 hexon hypervariable loops is more negative
than that of Ad26/Ad35/Ad48/Ad50 (S1 Table). Protection from neutralisation by FX is also
evident for Ad5 in rat serum (S1 Fig.).
Next we investigated the role of different capsid proteins in mediating Ad5 neutralisation. For
this we employed a range of Ad5-based chimeric vectors (S2 Table). We found no role for the
fiber or penton base, as swapping those of Ad5 for those of Ad35 (i.e. the Ad5.F35 and Ad5.
F35P35 vectors), still resulted in vector neutralisation in the absence of FX (Fig. 1B). Next we as-
sessed the contribution of the Ad5 hexon in enabling neutralisation. Here we utilised Ad5.
HVR48(1–7), which we previously showed to lack FX binding [24] (S2 Table). Ad5.HVR48(1–7)
was not inhibited by serum components regardless of FX, thus illustrating an essential require-
ment for the Ad5 hexon HVRs in mediating neutralisation via this mechanism (Fig. 1C). In addi-
tion, unlike the parental Ad5, the Ad5.HVR48(1–7) chimeric vector caused no induction of C3
activation in serum preincubated with X-bp (Fig. 1D). Hence, Ad5.HVR48(1–7) cannot bind to
FX [24] and is not sensitive to neutralisation. Therefore these data indicate a pivotal role for the
Ad5 HVRs in enabling immune attack via the IgM/classical complement pathway.
Sensitivity of Ad5 HVRmutant/FX-binding deficient viruses to
neutralisation
To investigate the contribution of different Ad5 HVRs in mediating neutralisation by mouse
serum, we evaluated the sensitivity of Ad5 vectors containing a range of Ad26 HVR
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modifications. Ad26 was chosen for these studies as it does not bind FX [24] and is not suscep-
tible to serum neutralisation in vitro (Fig. 1A). This series of Ad5/26 chimeric vectors (Ad5.
HVR5(Ad26), Ad5.HVR7(Ad26) and Ad5.HVR5+7(Ad26)) (S2 Table) were previously shown
to lack FX binding [32]. Unlike the Ad5 control, the Ad5 vectors with HVR(Ad26) swaps were
all sensitive to inhibition by serum (Fig. 2A), suggesting the involvement of multiple HVRs in
enabling neutralisation. Next, we employed a series of Ad5 vectors engineered with individual
point mutations to alter specific amino acids to those found in Ad26 (S2 Table). These vectors
were previously demonstrated to have reduced but not eliminated (e.g. Ad5.HVR5 (HVR5
mutations T270P and E271G) or abolished FX binding (e.g. Ad5.HVR7 (HVR7 mutations
I421G, T423N, E424S, L426Y) and Ad5.HVR5.HVR7.E451Q (hereafter referred to as
Ad5T)) [32]. We evaluated vector sensitivity to neutralisation over a range of concentrations
of C57BL/6 mouse serum (1–90% final volume) in vitro (Fig. 2B, S2 Fig.). In contrast to the
media control, transduction of all FX-binding deficient Ad5 vectors was dramatically reduced
in the presence of serum (Fig. 2B, S2 Fig.). This inhibitory effect was significantly lessened at
lower serum concentrations (<25%) for the vectors engineered with point mutations, Ad5.
E451Q, Ad5.HVR5, Ad5.HVR7 and Ad5T compared to vectors with entire HVR exchanges
Ad5.HVR5+7(Ad26) (Fig. 2B). The latter vector remained highly sensitive to neutralisation
even in the presence of 5% serum. This suggests that the sensitivity to serum is influenced by
Fig 1. Ad5 HVRsmediate neutralisation by naïvemurine serum. SKOV3 (A) or A549 cells (B-C): Vectors (2x1010 vp/mL) were incubated with RPMI-1640
media, 90% C57BL/6 mouse serum in RPMI-1640 media in the absence or presence of 40 μg/mL Xbp for 30 min at 37°C. Virus suspensions were diluted
200-fold in serum-free media and 100 μL added to cells for 2 h at 37°C before being replaced with RPMI-1640 media with 2% FCS. Transgene expression
was quantified*16 h post-transduction and relative light units (RLU) normalized to mg total protein. Results for each vector are shown as percentage of the
matched media control. White bars = media alone, grey bars = serum and black bars = serum + Xbp. (D) C57BL/6 mouse serum was incubated with Ad
(5x1010 vp/mL) in the presence or absence of 40 μg/mL Xbp for 90 min at 37°C. C3a levels were quantified by ELISA. *p< 0.005 vs. matched controls.
doi:10.1371/journal.ppat.1004673.g001
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the location and extent of modifications to the Ad5 HVRs, and is, at least, partially independent
of the complete loss of FX-binding capacity.
It has previously been shown that Ad5.HVR5 is capable of direct interaction with FX, albe-
it at lower levels than Ad5, however detailed affinity kinetics are not available [32]. We
Fig 2. Neutralisation of FX-binding deficient Ad5 vectors by naïve murine serum. (A) A549 and (B) SKOV3 cells: Ad5 and its derivatives (2x1010 vp/mL)
were incubated with RPMI-1640 media, 90% C57BL/6 mouse serum or 1–90%C57BL/6 mouse serum in RPMI-1640 media for 30 min at 37°C and (C) A549
cells: Ad5T* or Ad5.HVR5* (2x1010 vp/mL) were incubated with RPMI-1640 media, 1–90%C57BL/6 mouse serum in RPMI-1640 media in the absence or
presence of 10 μg/mL hFX for 30 min at 37°C. Virus suspensions were diluted 200-fold in serum-free media and 100 μL added to cells for 2 h at 37°C before
being replaced with RPMI-1640 media with 2% FCS. Transgene expression was quantified*16 h post-transduction and relative light units (RLU) normalized
to mg total protein. Results for each vector are shown as percentage of the matched media control. Groups that do not share the same letter (a, b, c, d) are
significantly different to samples within that group. *p< 0.05 vs. matched controls.
doi:10.1371/journal.ppat.1004673.g002
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hypothesized that immune components may compete with FX for binding sites within related
exposed Ad5 HVR loops. Notably we found the concentration of hFX in human serum to be
*50% lower than that of normal plasma (S3 Table). To test whether increasing concentrations
of FX could protect Ad5.HVR5 from immune attack, we spiked C57BL/6 mouse serum with
10 μg/mL hFX and examined the susceptibility of the non-FX-binding Ad5T control vector
and Ad5.HVR5 to neutralisation (Fig. 2C). As expected the presence of hFX did not affect the
neutralisation of Ad5T by serum and mediated no increase in gene transfer (Fig. 2C). Howev-
er, hFX prevented neutralisation of Ad5.HVR5, particularly in lower concentrations of serum
(Fig. 2C). The presence of hFX also increased gene transfer of Ad5.HVR5 indicating its ability
to both protect and act as a bridge to HSPGs despite sub-optimal FX:hexon binding conditions
[24]. These data indicate that both hFX and the murine serum components can compete with
one another, likely through binding to similar HVRs, and this is dependent on their relative
concentrations and/or affinities.
Generation and analysis of recombinant Ad26 virus containing
modifications in hexon HVRs
To further dissect the role of the Ad5 HVRs and FX in protecting Ad from serum neutralisa-
tion, we engineered FX binding capacity into Ad26 by substituting the Ad5 HVRs into the
Ad26 hexon. We attempted to generate a number of Ad26-based mutants however only three
Ad26 chimeras were successfully packaged into mature viral vectors at high titer (Fig. 3A, S3
Fig., S4 Table). Specific hexon sequences were chosen for mutagenesis (S3 Fig.). These included
the point mutant Ad26.Q461E (the corresponding Glu residue is conserved in all FX binding
Ads) and the HVR exchanges Ad26.HVR5(Ad5).Q461E and Ad26.HVR5C [in which Ad26.
HVR(1–3 and 5–7) were replaced by those of Ad5], respectively (Fig. 3A, S4 Table, S3 Fig.). To
note, due to the genetic capsid modifications the vp:PFU ratio was*10 fold higher for both
Ad26.HVR5C and Ad26.HVR5(Ad5).Q461E compared to the parental Ad26 vector (Fig. 3A).
We next measured the ability of each virus to bind hFX by SPR. Ad26.HVR5C showed efficient
binding when injected over a hFX biosensor chip, as did the positive control Ad5, while Ad26,
Ad26.Q461E and Ad26.HVR5(Ad5).Q461E did not bind hFX (Fig. 3B). We then quantified af-
finity kinetics (Fig. 3C). The calculated association rate constant (ka) and dissociation rate con-
stant (kd) values of the hFX for immobilized Ad26.HVR5C were 3.085x106 (1/Ms) and
1.068x10–2 (1/s), giving an overall equilibrium dissociation constant (KD) of 3.462x10–9
M. When Ad5 was immobilized and hFX was injected across the biosensor, ka and kd values
were 1.308x106 (1/Ms) and 3.053x10–3 (1/s), giving a KD of 2.334x10–9 M (Fig. 3C), consistent
with previously reported kinetics [24]. Therefore, incorporation of Ad5 HVR(1–3 and 5–7)
into Ad26 generates de novo binding to FX by Ad26 at an affinity similar to Ad5.
Effect of de novo FX binding and Ad5 HVR inclusion on Ad26 sensitivity
to mouse serum
Ad26.HVR5C provides a novel virus through which to ascertain whether inclusion of Ad5
HVR(1–3, 5–7) are sufficient for exposure to neutralisation and whether FX binding influenced
the sensitivity of the parental virus to mouse serum. Therefore we assessed cellular transduc-
tion by the Ad26 mutants in the absence and presence of C57BL/6 or RAG2-/- murine sera
+/- X-bp. RAG2-/- mice are immune-deficient, lacking mature T and B lymphocytes, closely
related to the RAG1-/- strain in which Ad5 liver tropism was previously demonstrated to be FX
independent [19]. Parental Ad26 was resistant to neutralization by both strains of serum re-
gardless of FX, again demonstrating Ad26 is not sensitive to the same mechanism that mediates
Ad5 neutralisation (Fig. 4A). Interestingly, Ad26.HVR5C was resistant to neutralization in the
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presence of FX but sensitive to neutralization when immune-competent C57BL/6 serum was
pre-incubated with X-bp, a similar profile to that seen with Ad5 (Fig. 4A). RAG2-/- serum did
not neutralize Ad26.HVR5C or Ad5 (Fig. 4A), indicating a requirement for efficient T and/or
B cell antibody function [19]. Ad26.HVR5(Ad5).Q461E and Ad26.Q461E were unaffected by
either sera regardless of the presence of FX. Furthermore, whilst there were differences
amongst the basal levels of C3a between vectors, both Ad5 and Ad26.HVR5C, but not Ad26
enhanced C3a in a FX-dependent manner. Notably, the FX protection mechanism is not de-
pendent on the heparin binding exosite in the FX serine protease domain, as blocking these
HSPG interacting sites did not alter Ad induced C3a levels compared to the matched serum
only control (Fig. 4C). Hence, inclusion of the Ad5 HVRs in Ad26.HVR5C not only leads to
FX binding, but also sensitises the virus to attack in immune-competent mouse serum indicat-
ing the importance of these hexon regions in both FX binding and immune recognition.
Effect of FX binding on recombinant Ad26 tropism
We next investigated whether creating Ads engineered to bind FX influenced their ability to in-
teract with cells in vitro and in vivo. We performed cell binding and transduction assays with
Fig 3. Generation of Ad26 hexonmodified vectors and effects on FX binding by SPR. (A) Virus titers and vp/pfu ratios for each of the vectors produced.
(B) SPR analysis of Ad5, Ad26 and mutant vector interaction with immobilized hFX (500 RU). Sensorgrams of 1011 vp/ml of vector injected at a flow rate of
30 μL/min. (C i) SPR analysis of hFX for immobilized Ad26.HVR5C. Samples analysed in triplicate at 4 concentrations of hFX. (C ii) SPR analysis of hFX for
immobilized Ad5. Samples analysed in triplicate at 7 concentrations of hFX. The black lines represent the fit to the data. (C iii) Kinetic constants of hFX for
immobilized Ad5 or Ad26.HVR5C as determined by SPR.
doi:10.1371/journal.ppat.1004673.g003
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Ad26.HVR5C to assess vector:cell interaction profiles (Fig. 5). SKOV3 cells were employed for
these assays as they express low levels of CAR [39] and allow focus on the FX-mediated path-
way. Both cell binding and transduction for Ad26.HVR5C were significantly increased in the
presence of FX compared to the parental Ad26 which was unaffected by FX (Fig. 5A-B). This
suggests that Ad26.HVR5C functionally binds FX leading to Ad:FX engagement with cellular
HSPGs and subsequent gene transfer. Next, we examined whether the Ad26.HVR5C hexon:FX
interaction generates hepatic tropism via FX bridging to hepatocytes [24,33,34]. Immune com-
petent MF1 control mice were first treated with warfarin to deplete vitamin K-dependent coag-
ulation factors, and then administered I.V. with 1011 vp of Ad5, Ad26 or Ad26.HVR5C.luc+.
Luciferase expression was visualised by whole-body bioluminescence imaging and quantified
at 72 h. Ad26 produced low level, widely biodistributed gene transfer and this was unaltered by
warfarin (Fig. 6A). However, both Ad5 and Ad26.HVR5C produced selective transduction of
the liver in non-warfarin treated mice (Fig. 6A-C) albeit the levels mediated by Ad26.HVR5C
were significantly lower than those of Ad5. Despite the vp:PFU ratio of Ad26.HVR5C being
Fig 4. FX protects Ad26.HVR5C against immune attack. (A) 2x1010 vp/mL of Ad5, Ad26 or Ad26 hexon modified vectors were incubated with RPMI-1640
media, 90% C57BL/6 mouse serum, 90% C57BL/6 mouse serum with 40 μg/mL X-bp, 90% RAG2-/- mouse serum or 90% RAG2-/- mouse serum with X-bp,
for 30 min at 37°C. Virus suspensions were diluted 200-fold in serum-free media and 100 μL added to SKOV3 cells for 2 h at 37°C before being replaced with
RPMI-1640 media with 2% FCS. Transgene expression was quantified*16 h post-transduction and relative light units (RLU) normalized to mg total protein.
Results for each vector are shown as percentage of the matched media control. *p< 0.001 vs. matched media controls. (B) C57BL/6 mouse serum was
incubated with Ad (5x1010 vp/mL) in the presence or absence of 40 μg/mL Xbp for 90 min at 37°C. C3a levels were quantified by ELISA. (C) C57BL/6 mouse
serum was incubated with Ad5 or Ad5T* (5x1010 vp/mL) in the presence or absence of 20 μg/mL NapC2 for 90 min at 37°C. C3a levels were quantified by
ELISA. *p< 0.005 vs. matched controls.
doi:10.1371/journal.ppat.1004673.g004
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*10 fold lower than Ad26 (Fig. 3A), there was a significant increase in liver luciferase levels
for the Ad26.HVR5C vector compared to Ad26, in non-warfarin treated animals (Fig. 6C). For
both Ad5 and Ad26.HVR5C, liver transduction was reduced to less than 0.5% of control fol-
lowing warfarin treatment. Quantification of viral genome accumulation in the livers of Ad5
and Ad26.HVR5C injected animals revealed a similar pattern of virus-mediated gene transfer
(Fig. 6D). Thus, inclusion of FX binding into Ad26.HVR5C leads to profound retargeting ef-
fects following I.V. injection into MF1 mice.
Fig 5. FX-mediated Ad26.HVR5C cell surface binding and transduction. (A) Binding of 1000 or 5000 vp/
cell of Ad5, Ad26 or Ad26.HVR5C was quantified after incubation with SKOV3 cells for 1 h at 4°C in the
presence or absence of 10 μg/mL hFX. Vector genomes were detected by quantitative PCR. (B) SKOV3 cells
were infected with 1000 or 5000 vp/cell of Ad5, Ad26 or Ad26.HVR5C in the absence or presence of 10 μg/mL
hFX for 3 h at 37˚C, after which media was replaced by full RPMI-1640media and cells incubated at 37˚C.
Transgene expression was measured 48 h post-infection. *p< 0.001 vs. matched -/+FX controls.
doi:10.1371/journal.ppat.1004673.g005
The Ad5 Hexon HVRs Confer Sensitivity to Immune Attack
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Ad5 HVRs mediate immune sensitivity in vivo and FX dictates Ad26.
HVR5C hepatic tropism
We then performed the same experiment in immune-deficient RAG2-/- mice. Ad5 mediated
FX-independent liver transduction in RAG2-/- mice, similar to that previously reported in
RAG1-/- mice [19] (Fig. 7A-D). Ad26 demonstrated widespread gene expression in vivo which
was equivalent in both non-warfarin and warfarin-treated mice (Fig. 7A). However, Ad26.
HVR5C transduction was focused in the liver in non-warfarin treated RAG2-/- mice, whilst he-
patic gene expression was dramatically decreased in the absence of FX (Fig. 7A-C). The trans-
duction profile of Ad26.HVR5C in warfarin-treated mice was completely altered, no longer
targeting the liver but instead exhibiting a more widespread biodistribution similar to the pa-
rental Ad26 (Fig. 7A). This demonstrates the ability of the hexon:FX interaction to determine
Fig 6. In vivo analysis of Ad26.HVR5Cmediated liver transduction in MF1mice. (A + B) Luciferase expression was visualised (A) and quantitatively
assessed (B) by whole-body bioluminescence imaging 72 h after intravascular administration of 1x1011 vp/mouse Ad5, Ad26 or Ad26.HVR5C in the absence
or presence of 133 μg/mouse warfarin (n = 6 animals/group) or PBS (n = 3 animals/group) in MF1 mice. (C) Livers were harvested 72 h post vector injection
and processed for quantification of luciferase transgene expression and (D) quantification of viral genomes, using 200 ng of DNA for analysis. *p<0.05,
***p<0.001 and NS (not significant) vs the matched non-warfarin treated control.
doi:10.1371/journal.ppat.1004673.g006
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Ad26.HVR5C hepatocyte uptake. Through this gain-of-function approach, incorporation of
FX binding into Ad26, FX was shown to effectively alter vector tropism in vivo and dictate liver
targeting of Ad26.HVR5C in control and immune-deficient mice.
The high levels of gene expression by Ad5 in warfarin treated RAG2-/- mice (Fig. 7A) is in
contrast to the diminished luciferase expression (Fig. 6A) observed in warfarin treated MF1
mice. This is due to IgM and classical complement-mediated vector neutralisation, similar to
that demonstrated previously [19]. Unlike Ad26 but in parallel to Ad5, gene expression by
Ad26.HVR5C was also inhibited in warfarin treated MF1 mice but not warfarin treated
RAG2-/- mice (Fig. 6A, 7A). This suggests Ad26.HVR5C was neutralised in immune competent
mice as a direct consequence of the engineered Ad5 HVRs. This indicates that in the immune
competent setting, in the absence of a FX protective mechanism, engineering the Ad5 HVRs
into Ad26 confers sensitivity to immune attack and vector neutralisation in vivo.
Fig 7. In vivo analysis of Ad26.HVR5C biodistribution in immune deficient mice. (A + B) Luciferase expression was visualised (A) and quantitatively
assessed (B) by whole-body bioluminescence (IVIS) imaging 72 h after intravascular administration of 1x1011 vp/mouse Ad5, Ad26 or Ad26.HVR5C in the
absence or presence of 133 μg/mouse warfarin (n = 4 animals/group) or PBS (n = 3 animals/group) in RAG2-/- mice. (C) Livers were harvested 72 h post-
injection and processed for quantification of luciferase transgene expression and (D) quantification of viral genomes, using 200 ng of DNA for analysis.
*p<0.05 and NS (not significant) vs the matched non-warfarin treated control.
doi:10.1371/journal.ppat.1004673.g007
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Discussion
Here, the role of the Ad5 HVRs and the significance of FX in defending the virus from host at-
tack whilst determining liver targeting are described. We first identified the Ad5 HVRs as re-
sponsible for conferring sensitivity to serum neutralisation. We then genetically engineered the
Ad5 hexon loops, onto a non-FX-binding Ad26 background to generate the novel vector Ad26.
HVR5C. Employing this as an efficient tool, we deciphered the importance of Ad5 HVRs and
FX in immune recognition, protection and biodistribution following systemic
Ad administration.
Previous work reported that coagulation FX coats Ad5 to protect from IgM and classical
complement-mediated immune neutralisation and that Ad5 liver uptake was not solely depen-
dent on FX under immune-deficient conditions [19]. However the capsid proteins to which
IgM and the classical complement components bind and initiate this cascade eventually leading
to virus inactivation have not been identified. In addition to this work, Doronin et al., indicated
that displacement of FX from the coagulation system through binding to Ad5 is sensed by the
host and an inflammatory response is initiated [37]. Therefore, with both of these recent stud-
ies in mind, we attempted to identify the Ad capsid regions responsible for mediating immune
neutralisation and further decipher the functional consequences of the Ad:FX interaction. We
began by showing the FX protection mechanism was not conserved amongst human Ads. Ad5
was the only type tested susceptible to serum neutralisation in the absence of FX and using a se-
ries of genetic and pharmacological approaches this was shown to be reliant on the presence of
the Ad5 HVRs. We then investigated the sensitivity of Ad5-based HVR mutants and FX-defi-
cient vectors to neutralisation by serum from immune-competent mice and found that all vi-
ruses were inhibited, but interestingly there were differences amongst these inactivation levels.
These variations indicate that it is more than simply the loss of FX binding or these contact
points which likely dictates immune recognition. For our experiments we used fresh mouse
serum. Unlike citrated or EDTA treated plasma there is no interference with calcium, which
has previously been found to influence results [18]. During the coagulation process, a propor-
tion of the coagulation factors will be activated and levels of intrinsic FX reduced. When we in-
vestigated the effects of spiking mouse serum with hFX and compared the null-binder Ad5T
to the FX-defective binder Ad5.HVR5, we found hFX was capable of rescuing Ad5.HVR5
from neutralisation and further increasing gene transfer to levels above the media control.
These data thereby suggests that hFX and the inhibitory murine serum components compete
for binding within similar regions within the Ad5 hexon. Interestingly previous data has dem-
onstrated using targeted PEGylation that similar Ad5 HVRs (1, 2, 5 and 7) are also responsible
for interacting with scavenger receptors and subsequent Kupffer cell uptake, but in that case
it has been suggested that FX and the scavenger receptors do not have overlapping binding
sites [40].
Our work demonstrates a key role for the Ad5 HVRs in determining virus sensitivity to
serum. We successfully engineered an Ad26 vector with Ad5-derived HVRs, Ad26.HVR5C,
capable of FX-mediated cell binding and transduction in vitro. The species D Ad26 is a less ser-
oprevalent virus than Ad5 [14]. It has been shown to utilise both CD46 [41] and CAR [42] as
primary cellular receptors and is currently gaining a lot of attention as a vector-based vaccine
against HIV [43]. Interestingly, the Ad5 HVR(1–3, 5–7) exchange in this Ad26-based vector
suddenly made the virus susceptible to neutralisation by mouse serum, indicating the driving
influence of the HVRs and the likelihood they possess a critical IgM recognising epitope. The
smaller regions of exchange in Ad26.HVR5(Ad5).Q461E or the single point mutation in Ad26.
Q461E were not sufficient to induce sensitivity to neutralisation. Conversely, incorporating the
Ad26 HVR5+7 into Ad5 resulted in a vector (Ad5.HVR5+7(Ad26)) that remained susceptible
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to the inhibitory effects of serum. This indicates it is perhaps likely that multiple HVR loops
working in conjunction which are responsible for mediating the crucial serum binding event. It
will require further study to fine map the essential contact sites. IgM antibodies are broadly re-
active, capable of binding to unrelated structures with low affinity [44] and mostly exist as a
pentameric structure, containing ten potential antigen binding sites [45]. Therefore it is possi-
ble one IgM molecule may be capable of interacting across a wide hexon region. These natural
antibodies are often directed against highly repetitive and charged motifs [46,47]. A recent
study suggested the involvement of the electronegative potential of antigens in IgM recognition
[47]. To note, the panel of recombinant Ad5-based FX-binding deficient viruses, with the point
mutations were all modulated to have lower net negative charge, whilst the more sensitive en-
tire HVR exchanges in Ad5.HVR5+7(Ad26) had more negative charge compared to the paren-
tal vector (S1 Table). In addition it is perhaps interesting that the net charge of the Ad5 hexon
protein is more negative than the other vectors tested in this study, Ad26/Ad35/Ad48/Ad50.
The HVRs of Ad types tested here differ significantly and charge-specific mutation analysis is
required to further address this potential issue.
Engineering FX-binding into the Ad26 vector had profound effects on viral biodistribution
in in vivomodels of viral dissemination. In complete contrast to its parental virus, Ad26.
HVR5C exhibited selective liver gene transfer in the presence of FX in immune-competent and
deficient mice. In the absence of FX and immunity, Ad26.HVR5C reverted to its native tro-
pism, with the same biodistribution pattern as Ad26. This demonstrates the tropism defining
force instilled by the inclusion of FX binding. The interaction with FX instils new tropism in
addition to its native Ad26 receptor usage (e.g. via CAR/CD46) [41,42]. It is evident from the
work presented here, and from others [19], that Ad5 remains hepatotropic in warfarin treated
immune-deficient mice. Therefore this suggests, that an alternative mechanism is utilised by
Ad5 to transduce hepatocytes of immune deficient animals when FX binding is diminished.
Further investigation is required to answer the important question of what is the precise mech-
anism determining Ad5 liver targeting in the absence of FX.
The relevance of the Ad:FX interactions and protection pathways in humans suffering from
the disseminated disease is yet to be examined. Further study is therefore required to investi-
gate whether human natural IgM can bind to Ads and if this initiates similar pathways as those
in the mouse i.e. classical complement mediated neutralisation in the absence of FX [19]. It
may also be beneficial to directly compare and interrogate the influences and interplay of com-
plement, natural and acquired human immunoglobulins [48]. This may help to better predict
the human immune defense to widespread Ad infection or when using Ads as gene therapy
vectors. In the general population the majority of specific neutralising antibodies (e.g. IgG-
based) are directed against the Ad5 hexon protein and particularly focused on the Ad5 HVRs
[49,50]. Previous work has demonstrated that such neutralising human sera can prevent FX-
mediated cellular binding and transduction in vitro [51]. In addition, in MF-1 mice preinjected
with human sera, higher levels of pre-existing neutralising antibodies, correlated with de-
creased hepatocyte transduction in the presence of FX [51]. It would be interesting to deter-
mine whether different families of human immunoglobulins (IgG/IgM/IgA) can compete for
binding sites within the Ad hexon HVRs, the relative affinities of these interactions and, fur-
ther, whether FX coating of the hexon affects these processes. This would also be of clinical rel-
evance in terms of gene therapy and for determining patient suitability or the type of Ad vector
employed (FX-binding or non-FX-binding vectors) for intravascular Ad administration. Inves-
tigating the relevance of the FX protection mechanism from rodent to human models is an im-
portant next step for the field. Evidently, the complexity of Ad interactions with host factors is
extensive and small animal models may only provide limited information. For instance, CAR-
mediated Ad5 binding to human erythrocytes is an important clinical consideration however
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mouse erythrocytes are devoid of CAR expression, again highlighting the necessity for using
human samples [22,52,53].
Despite the high morbidity and mortality rate associated with disseminated Ad infection
there are currently no licensed specific anti-adenoviral drugs available for the management of
the condition. Those that have been used in clinical settings, such as ribavirin, cidofovir, and
vidarabiner, have yielded varied results and treatment options remain largely unsatisfactory
[54,55]. A previous study identified small molecule pharmacological agents to block FX-medi-
ated Ad5 infection following intravenous administration in a mouse model, and found it to be
an effective strategy by which to prevent hepatic targeting [56]. However, in that case the phar-
macological inhibitor was acting post the Ad5:FX binding event [56]. Doronin et al. used
cryoEM and molecular dynamics flexible fitting simulations techniques to reveal an interaction
between the FX Gla K10 residue and the Ad5 HVR7 residues E424 and T425 [37]. From our
work it is evident that the host natural IgM and classical complement mediated defence mecha-
nism is effectively governed via the Ad5 HVR loops, immune recognition is dependent on
more than solely the loss of FX contact points, and FX functions in mediating liver uptake in
both immune competent and deficient models. Identification of a small molecule inhibitor
with favourable pharmacological properties capable of specifically blocking the Ad5:FX inter-
action at these contact points may enable a more robust host anti-viral immune response whilst
limiting liver infection and thus be very valuable in treating systemic disease.
In summary, here we have identified the Ad5 HVRs as the key regions conferring sensitivity
to the IgM and complement mediated host defence pathway. FX has both a pivotal role in pro-
tecting the virus from attack and has profound effects on Ad biodistribution. Through this
work we gain a greater insight into the mechanism and significance of FX in protecting Ads
against innate immunity and determining virus tropism.
Materials and Methods
Ethics statement
All animal procedures were approved by the University of Glasgow Animal Procedures and
Ethics Committee and performed under UK Home Office license PPL 60/4429 in strict accor-
dance with UK Home Office guidelines. All efforts were made to minimize suffering.
Cells
HEK293 (human embryonic kidney: ATCC CRL-1573) and HeLa (human cervical adenocarci-
noma: ATCC CCL-2) cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM;
Invitrogen, Paisley, UK) and SKOV3 (human ovarian carcinoma: ATCC HTB-77) and A549
(human lung carcinoma: ATCC CCL-185) cells in RPMI-1640 medium (Invitrogen), with 2
mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS; PAA Laboratories) and 1 mM sodi-
um pyruvate (Sigma-Aldrich, UK) at 37°C 5% CO2. PER.C6/55K cells [57] were cultured in
DMEM with 2 mM L-glutamine, 10% FCS, 1 mM sodium pyruvate and 10 mMMgCl2, at 37°C
10% CO2.
Vector construction
E1/E3 deleted Ad5, Ad35, Ad5/35 chimeras (Ad5.F35, Ad5.F35P35), Ad26, Ad50, Ad48 and
Ad5/48 chimeric (Ad5.HVR48(1–7)) vectors encoding CMV-luciferase reporter genes were
generated as described previously [14,24,58]. S2 and S4 Tables provide detail on each of the
mutated vectors used in this study. E1/E3 deleted Ad5 and FX-binding deficient Ad5/Ad26 chi-
meric vectors (Ad5.HVR5+7(Ad26), Ad5.HVR5, Ad5HVR7, Ad5E451Q and Ad5T)
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encoding CMV-lacz reporter genes were generated as described previously [32]. Hexon gene-
modified Ad26 vector genomes were constructed in the context of pAd26.luc, a plasmid that
contains a PacI site-flanked, full-length Ad26 vector genome with E1, E3, and E4 deletions/
modifications [14]. The vector genome is further equipped, at the site of E1 deletion, with a
CMV promoter-driven expression cassette for firefly luciferase. To generate the desired hexon
gene-modified pAd26.luc plasmids, the concerning Ad26/Ad5 hexon modifications (S4 Table)
were first made in the context of a smaller ‘hexon shuttle’ plasmid (gene synthesis and subclon-
ing by GeneArt/LifeTechnologies), and then shuttled into a hexon gene-deleted derivative of
pAd26.luc by homologous recombination in E.coli BJ5183 (Stratagene/Agilent Technologies),
as described previously [32]. S3 and S4 Figs. further describe construction and Ad26/Ad5 se-
quence alignment, highlighting the regions targeted for mutagenesis.
Vector amplification
Linearised Ad plasmids were transfected in PER.C6/55K using Lipofectamine 2000 (Invitro-
gen). Cells were harvested 10–14 days post-transfection. Viral particles (vp) were propagated
and purified by CsCl gradients. Titers were determining by protein concentrations using
micro-bicinchoninic acid (BCA) Protein Assay (Thermo Scientific). Titer calculations used the
formula 1 μg protein = 4x109 vp and end-point dilution assays using PER.C6/55K for quantifi-
cation of plaque forming units (pfu)/mL [59]. Purified Ads were analysed by SDS-PAGE fol-
lowed by silver staining (Sigma-Aldrich) according to manufacturer’s instructions in order to
verify the capsid composition and confirm the vector modifications did not interfere with the
structural integrity of the particles.
Surface plasmon resonance (SPR)
Immobilized hFX: Performed using Biacore 2000 (GE Healthcare) as described [31]. Purified
hFX was purchased from Cambridge Biosciences (Cambridge, UK). hFX was covalently immo-
bilized onto the flowcell of a CM5 biosensor chip by amine coupling. Immobilized Ad: Per-
formed using T200 (GE Healthcare). Virus was biotinylated using the EZ-link sulfo-NHS-LC
biotinylation kit (ThermoFisher). The biotinylated products were coupled to streptavidin-coat-
ed sensorchips (SA; Biacore); Ad5 (482RU), Ad26.HVR5C (484RU). SPR was performed in
10 mMHEPES (pH7.4) 150 mMNaCl, 5 mM CaCl2, 0.005% Tween20 at a flow rate of 30 μL/
min and sensorchips were regenerated by injection of 10 mMHEPES (pH 7.4) 150 mMNaCL,
3 mM EDTA, 0.005% Tween20. Kinetic analysis was performed using 2-fold serial dilutions (in
duplicate, starting with 30 μg/mL) of hFX and fitted using a 1:1 binding model (Biacore Evalua-
tion software, Biacore).
Cell binding assay
Cells were plated in 24-well formats (2x105 cells/well) and incubated overnight at 37˚C. Cells
were cooled (4°C) for 30 min, washed with phosphate buffered saline (PBS) before adding 1000
or 5000 vp/cell Ad -/+ hFX. hFX was used at 10 μg/ml. Cells were incubated for 1 h at 4°C,
washed with PBS, and harvested. DNA was extracted from cells using the QIAamp DNAmini
kit (Qiagen) and quantified using Nanodrop (ThermoScientific). Viral genomes (200 ng DNA)
were quantified by quantitative polymerase chain reaction (PCR) analysis (7900HT Sequence
Detection System; Applied Biosystems) using Power SYBR Green PCR mastermix and CMV
primers (Applied Biosystems).
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Transduction assay
Cells were plated in 96-well formats (1x104 cells/well) and incubated overnight at 37˚C. Cells
were infected with 1000 or 5000 vp/cell Ad -/+ hFX. Cells were incubated for 3 h at 37°C,
washed with PBS, maintained with medium and harvested 48 h post-transfection. Luciferase
activity was measured using the luciferase assay (Promega, Southhampton, UK). Protein con-
centrations were calculated by BCA. Values expressed as relative light units (RLU)/mg
of protein.
In vivo transduction
8–9 week old male MF1 outbred mice (Harlan, UK) and Rag2 knockout mice (on a C57BL/6
genetic background) (kind gift from Dr Alison Michie, University of Glasgow) were used. Mice
were warfarin-treated (133 μg/mouse) prior to virus administration as previously described
[24]. 1011 vp of Ad in 100 μL PBS were administered via tail vein injection. 72 h post-injection
IVIS imaging was performed and animals were sacrificed. Livers were harvested and luciferase
activity measured. DNA was extracted from livers using the QIAamp DNAmini kit. Viral ge-
nomes in 200 ng DNA were quantified by qPCR as above.
Serum neutralization assay
Cells were plated in 96-well formats (1x104 cells/well) and incubated overnight at 37˚C. Fresh
serum from C57BL/6 mice, Rag2-/- mice or Wistar rats was separated from whole blood, dilut-
ed in RPMI-1640 and incubated with 2x1010 vp/mL Ad in a final volume of 50 μL. 40 μg/mL
X-bp was added to samples to block FX. Where specified serum was spiked with 10 μg/mL hFX
prior to Ad addition. Controls were vectors alone in serum-free medium. Vectors were incu-
bated with serum or medium for 30 min at 37°C. Mixtures were diluted 200-fold in serum-free
medium. 1000 vp/well was added for 2 h at 37°C, then replaced with medium containing 2%
FBS. After*16 h, cells were harvested for determination of transgene expression and
protein content.
C3a ELISA
Serum was separated from fresh murine blood. Virus (5x1010 vp/mL) was incubated with
50 μL of serum-/+ 40 μg/mL Xbp or 20 μg/mL NapC2 (a kind gift from Dr G. Vlasuk (Corvas
International, San Diego, CA, USA)) for 90 min at 37°C, then 10 mM EDTA was added. Sam-
ples were frozen at -80°C until evaluation in a mouse C3a ELISA as previously described [18].
The capture antibody for ELISA was rat anti-mouse C3a (BD Pharmingen #558250) and the
detection antibody used was biotin rat anti-mouse C3a (BD Pharmingen #558251).
FX ELISA
The levels of hFX in human serum and plasma samples were measured using a Matched-pair
antibody for ELISA of human Factor X FX-EIA (Quadratech Diagnostics, Surrey, UK) accord-
ing to the manufacturer’s instructions. Purified hFX (Cambridge Bioscience) was used as
the control.
Statistical analysis
Statistical significance was calculated using one-way ANOVA followed by Bonferroni post-hoc
test with GraphPad Prism. In vitro results presented are representative data from three separate
experiments with at least 3 experimental replicates per group. Each in vivo experiment was
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performed with a minimum of 3 animals per group (n = 4–6 for Ad treated groups, n = 3 for
PBS groups). All error bars represent SEM.
Supporting Information
S1 Fig. Sensitivity to neutralisation by serum from other species. (A) Ad5 (2x1010 vp/mL)
was incubated with RPMI-1640 media, 90% C57BL/6 mouse or Wistar rat serum in the ab-
sence or presence of 40 μg/mL X-bp for 30 min at 37°C. Virus suspensions were diluted 200-
fold in serum-free media and 100 μL added to SKOV3 cells for 2 h at 37°C and then replaced
with RPMI-1640 media with 2% FCS. Transgene expression was quantified*16 h post-trans-
duction and relative light units (RLU) normalized to mg total protein. p<0.001 vs. species
matched media control.
(TIF)
S2 Fig. Neutralization of a series of FX-binding deficient Ad5 vectors by mouse serum. (A)
Ad5 and the FX-binding deficient derivatives (2x1010 vp/mL of each vector) were incubated
with RPMI-1640 media or 90% C57BL/6 mouse serum in the absence or presence of 40 μg/mL
X-bp, for 30 min at 37°C. Virus suspensions were diluted 200-fold in serum-free media and
100 μL added to SKOV3 cells for 2 h at 37°C before being replaced with RPMI-1640 media
with 2% FCS. Transgene expression was quantified*16 h post-transduction and relative light
units (RLU) normalized to mg total protein. Graphs show transduction as a percentage of con-
trol (Ad transduction with serum free media alone). p<0.001 vs. matched the control.
(TIF)
S3 Fig. Sequence alignment. Amino acid sequence alignment of the Ad5 and Ad26 hexon
HVR regions to highlight domains (HVR1, HVR2, HVR3, HVR4, HVR6 and HVR7, black
box; HVR5, two blue boxes) and amino acids targeted for mutagenesis studies (point mutations
highlighted by ). Ad26.HVR5C = Ad26 vector in which the Ad26 HVR1–3 and 5–7 were
swapped with that of Ad5.
(TIF)
S4 Fig. Procedure to generate hexon-modified Ad26 vectors. (A) Hexon sequence fragments
containing the desired hexon modifications were gene synthesized and subcloned, as AgeI-
BamHI restriction fragments, in place of the corresponding fragment within the ‘hexon shuttle’
plasmid pHex26-Shuttle.BamHI. This plasmid carries, between two PacI sites, a 6362-bp Ad26
genomic segment (corresponding to nucleotides 15755 to 22116 of genbank accession number
EF153474) encompassing the hexon coding sequence as well as left and right flanking se-
quences of 2 and 1.5 Kbp, respectively. The unique BamHI site present in the hexon coding se-
quence within this plasmid had been introduced by a silent mutation of a cytosine to thymine
at a position corresponding to position 19365 in EF153474. (B) The hexon modifications were
subsequently introduced into the Ad26 vector genome by homologous recombination (in E.
coli) between PacI-digested hexon shuttle plasmids (containing the desired modifications) and
SwaI-digested pAd26.luc.dH. This latter plasmid is a derivative of pAd26.luc that carries, be-
tween two PacI sites, an Ad26.luc vector genome whose hexon gene is replaced by SwaI sites.
(C) Hexon-modified Ad26 vectors were finally rescued by digestion of the hexon-modified vec-
tor genome plasmids by PacI and transfection of the resultant digestion products into E1-
complementing cells.
(TIF)
S1 Table. Ad vector charge. Partial hexon amino acid sequences including the HVRs of Ad5,
Ad50, Ad35, Ad26, Ad48 and chimeric vectors (see S3 Fig. for Ad5 reference sequence) were
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aligned. The net protein charges at pH 7.0 were calculated using CLC Genomics Workbench
6.0.5. protein analysis software.
(TIF)
S2 Table. Summary of the Ad5/35/48/26 chimeric vectors. Description of the regions
swapped in the chimeric vectors and their ability to bind to FX.
(TIF)
S3 Table. hFX concentrations in plasma and serum. An ELISA was used to measure the con-
centration of FX in human plasma and serum samples.
(TIF)
S4 Table. Ad26 based plasmids constructed. Summary of all Ad26-based plasmid systems
constructed and the ability to rescue virus particles in PER.C6/55K cells.
(TIF)
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